GCCA
23.8.2021 13:02:11 CEST | Business Wire | Press release
The third annual GCCA “Concrete in Life” photography competition has today launched with a call for amateur and professional photographers from around the world to capture the role of concrete in their lives and its role in the sustainable world of tomorrow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005132/en/
Concrete plays a key role in supporting society around the world. Its durability, strength, resilience and boundless versatility means it can be used for nearly any application, while its properties such as thermal mass, recyclability and carbon uptake make it the most sustainable building material.
Judges include Isabel Allen, Editor at Architecture Today, Gian Luca Barone from Zaha Hadid Architects and experts from the Global Cement and Concrete Association (GCCA). They will be looking for entries showing concrete contributing to their individual lives and wider society, and notably sustainable buildings and infrastructure, to inspire the public in the run up to COP26, as the GCCA prepares to announce its detailed roadmap to zero carbon concrete.
Contestants are invited to capture imagery in the following categories, which include a brand new Sustainable Concrete category:
- Urban design and use – images of the city landscapes and buildings around us, both well-known and hidden away
- Infrastructure – photographs of our infrastructure, in our cities and rural, above and below ground
- Concrete in daily life – the human side of concrete and how it’s used and interacted with daily
- Sustainable Concrete – how concrete is used in sustainable construction, buildings and infrastructure such as wind farms, dams, green overpasses, wildlife crossings, green buildings
The competition crown one winner for the professional and amateur brackets of each category as well as one overall winner for the “Best Concrete in Life” photo of the year from the eight finalists. Each category winner will receive $2,500 in prize money, while the overall winner will receive $10,000.
Thomas Guillot, GCCA Chief Executive, said: “Being the world’s most used human-made product, concrete provides the foundation for so many lives. The competition is designed to capture that importance and demonstrate its versatility throughout society. Entries to the first two ‘Concrete in Life’ competitions from both professionals and amateurs were exceptional and managed to capture concrete’s strength, durability and resilience, and we’re so excited to be launching the third annual competition. We look forward to receiving a wide array of unique and inspiring entries from all over the world.”
The annual competition by the GCCA attracts tens of thousands of entries from professional and amateur photographers and challenges participants to capture photos that highlight the beauty of concrete and the vital role it plays in our society.
To enter the competition, participants should post a picture that they’ve taken on Instagram or Twitter using the hashtags #ConcreteInLife2021, #UrbanConcrete, #ConcreteInfrastructure, #ConcreteInDailyLife, and #SustainableConcrete. They should also tag the GCCA – @the.gcca on Instagram or @theGCCA on Twitter.
Winners will also be invited to speak about their images with the GCCA, with their images shared on GCCA’s website and social media channels.
Judging the entries are:
- Gian Luca Barone, Senior Associate, Zaha Hadid Architects
- John Fairley, Design Director, Curious Productions
- Thomas Guillot, GCCA Chief Executive
- Isabel Allen, Editor, Architecture Today
The competition will run until October 22nd 2021, with the winners announced during January 2022. Full competition details can be found at https://gccassociation.org/concreteinlife2021/
-ends-
About the GCCA:
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210823005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
